- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00296985
Continuous Cellsaver and Neurocognitive Decline Post Cardiac Surgery
The Impact of Continuous Flow Cellsaver on Neurocognitive Decline After Cardiac Surgery
Patients having cardiac surgery to correct their heart disease may suffer a decline in mental and neurologic abilities. Passage of small particles of fat, tissue waste and air bubbles to the brain while on the heart-lung machine is thought to be one cause for decline in mental and neurologic abilities (the function of brain) after surgery.
The purpose of this study is to determine if replacement of cardiotomy suction (one part of the heart-lung machine) with the cell-saver (a different part of the heart-lung machine) during surgery will help to prevent a decline in mental and neurologic abilities after surgery. investigating 312 patients over 2 years,patients will be assigned randomly to either cardiotomy suction or cell-saver group. Patients will be given questionnaires before surgery, 6 weeks and 1-year after surgery. These questionnaires will assess memory, attention span, the ability to concentrate and the quality of life. Patients will also have a brief neurologic exam (physical examination to check mental state, reflexes, strength, and balance) before surgery, 3-5 days after surgery, 6 weeks and 1-year after surgery to determine any changes. Cell-saver separates red blood cells from tissue waste products and fat prior to returning blood back to the patient and may reduce the negative effects of particles of fat, tissue waste and air bubbles have on the brain. Potential benefits of cell-saver device when used during surgery may prevent the decrease in memory, attention span, and the ability to concentrate resulting in improved quality of life after surgery.
Objectives: The primary aim is to determine the effect of continuous flow cell-saver on short and long term neurocognitive function after cardiac surgery, measured by precise preoperative and postoperative psychometric and neurologic testing. Hypothesis: The primary hypothesis: Continuous flow cell-saver reduces postoperative neurocognitive decline following cardiac surgery. Methodology: 312 informed and consenting patients, age > 65 years, scheduled for coronary artery bypass graft surgery will be prospectively enrolled over a 2-year period. Patients will be randomly allocated to either the continuous flow cell-saver or conventional cardiotomy suction (controls). Neurological history and physical exam will be completed preoperatively, discharge, 6-weeks and 1-year after surgery. Transcranial Doppler scanning will be used for intraoperative monitoring of cerebral embolic load. Transesophageal echocardiography and epiaortic scanning will be employed to account for the severity of the aortic atheroma scores. Neurocognitive testing and quality of life assessment will be conducted preoperatively , 6-weeks and 1-year after surgery. Significance: The utilization of continuous flow cell-saver may reduce the negative effects of fat particles, tissue waste and air emboli have on brain.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital, University Health Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 65 years,
- elective CABG surgery
- signed informed consent
Exclusion Criteria:
- Severe kidney (creatinine > 2.5mg/dL and
- liver disease (bilirubin > 2 mg/dL)
- symptomatic cerebrovascular disease
- alcoholism
- psychiatric illness
- patients who are unable to read or who have less than a 7th grade education.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary aim is to determine the effect of continuous flow cell-saver on short and long term neurocognitive function after cardiac surgery, measured by preoperative and postoperative psychometric and neurologic testing.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
A secondary aim is to determine if the improvement in cognitive function is associated with improved quality of life after cardiac surgery.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: George N Djaiani, MD, Toronto General Hospital, University Health Network
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UHN REB 01-0420-B
- HSFO NA4915
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Disease
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
University of PennsylvaniaCompleted
-
Abbott Medical DevicesRecruitingAortic Valve Disease | Valvular Heart DiseaseChina
-
Mansoura UniversitySuspendedValve Heart Disease | Elective Cesarean DeliveryEgypt
-
Assiut UniversityCompleted
-
Tulane UniversityCompletedCardiomyopathies | Valvular Heart Disease | Pericardial DiseaseUnited States
-
InnovHeartActive, not recruitingHeart Valve Diseases | Mitral Regurgitation | Valve Heart Disease | Mitral Valve Disease | Mitral DiseaseLithuania, Denmark, Hungary
-
Fundació Institut de Recerca de l'Hospital de la...UnknownValvular Heart Disease | Cardiac Disease | Nurse's Role | CompetenceSpain
-
Aarhus University Hospital SkejbyInstitute for Clinical and Experimental MedicineCompletedHeart Failure | Coronary Heart Disease | Ischemic Heart DiseasesDenmark
Clinical Trials on Fresenius Cellsaver
-
University Medical Center GroningenTerminated
-
Medical University of ViennaCompleted
-
Astellas Pharma China, Inc.CompletedKidney Transplant RecipientsChina
-
Kyungpook National University HospitalMinistry of Health & Welfare, Korea; Fresenius Medical Care KoreaCompletedKidney Failure, Chronic | Disorders Associated With Peritoneal DialysisKorea, Republic of
-
UConn HealthDialysis Clinic, Inc.; Nipro Medical CorporationCompleted
-
Lawson Health Research InstituteWestern University, CanadaCompletedCardiac Surgical Procedures
-
IRCCS Policlinico S. MatteoItalian Association for Pediatric Hematology OncologyUnknownPaediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated VolunteerItaly
-
Ullevaal University HospitalRikshospitalet University HospitalCompletedExtracorporeal Clotting During HemodialysisNorway
-
University College, LondonCompletedKidney Failure
-
YUAN Wei-jieUnknownMuscular Atrophy